Literature DB >> 16035571

Abdominopelvic perivascular epithelioid cell tumor with overt malignancy: a case report.

I-Yu Chen1, Sheau-Fang Yang, Fang-Ming Chen, Chee-Yin Chai.   

Abstract

Perivascular epithelioid cell tumor (PEComa) is a group of rare tumors composed of epithelioid cells with characteristic perivascular distribution and co-expression of the melanogenic marker HMB-45 and muscular markers. There are no documented parameters referring to the biologic behavior of PEComa. We report an abdominopelvic PEComa with overt malignancy in a 16-year-old girl. Histologically, the tumor showed the typical morphophenotypic characteristics of PEComa. Though the cytologic appearance of the tumor cells was relatively bland, the extensive necrosis, presence of lymph node metastases, and surrounding tissue invasion were all indicative of malignancy. Relapse of the tumor with multiple lymphadenopathy shortly after debulking surgery for the primary lesion, and postoperative adjuvant chemotherapy, further denoted its aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16035571     DOI: 10.1016/S1607-551X(09)70201-3

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  3 in total

1.  Perivascular epithelioid cell neoplasms (PEComas): four malignant cases expanding the histopathological spectrum and a description of a unique finding.

Authors:  Ilan Weinreb; David Howarth; Eleanor Latta; Danny Ghazarian; Runjan Chetty
Journal:  Virchows Arch       Date:  2007-02-15       Impact factor: 4.064

2.  Malignant perivascular epithelioid cell tumor arising in the mesentery: A case report.

Authors:  Yinghong Shi; Junzu Geng; Haizhu Xie; Bin Wang
Journal:  Oncol Lett       Date:  2015-03-13       Impact factor: 2.967

3.  Perivascular epithelioid cell tumor of the retroperitoneum in a young woman resulting in an abdominal chyloma.

Authors:  T E Lans; G H van Ramshorst; J J Hermans; M A den Bakker; T C K Tran; G Kazemier
Journal:  J Gastrointest Surg       Date:  2008-01-23       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.